Sygnature Discovery
Sygnature Discovery is a UK-headquartered, privately held contract research organization delivering integrated preclinical drug discovery from target identification to clinical candidate nomination for global biotech and pharmaceutical clients, with 700+ scientists across the UK and Canada.
- Company typePrivate
- Founded2003
- HeadquartersNottingham, United Kingdom
- Headcount1,001–5,000
- GTM typeB2B
- OfferingServices
What Sygnature Discovery does
Sygnature Discovery is a UK-headquartered, privately held contract research organization providing integrated preclinical drug discovery services to global biotechnology and pharmaceutical clients. The company delivers end-to-end programs from target identification through clinical candidate nomination, spanning target ID/validation, hit identification (HIT SYNERGY), hit-to-lead, lead optimization, and preclinical development. Its scientific stack combines computational chemistry, AI-enabled design, structural biology (X-ray crystallography, cryo-EM, NMR), medicinal and high-throughput chemistry, bioscience, DMPK, in vivo pharmacology, and formulation. Co-located multidisciplinary teams of 700+ scientists (70% PhDs, from 50+ countries) operate across UK sites in Nottingham, Alderley Park, Macclesfield, and Glasgow, and Canadian sites in Montreal and Lévis.
The business operates as a professional services CRO, generating revenue through project-based contracts, FTE allocations, milestone payments, and standalone scientific service engagements. GTM is sales-led and enterprise-focused, with no intermediaries or self-serve channels; distribution relies on direct field sales, inside sales for inbound qualification, and customer referrals reinforced by a 90%+ retention rate. Sygnature differentiates on proprietary platforms — SygDesign (informatics), CHARMED (PROTAC/targeted protein degradation), STRATA (17M+ compound virtual library), FMO-SP (quantum SBDD), and AI4Lit (literature analytics) — and integrates third-party AI tools (Iktos Makya, BullFrog AI, DaltonTx, AlphaFold). Since 2011 the company has delivered 61 pre-clinical and 38 clinical compounds, with one contributed therapy (relacorilant) receiving FDA approval as Lifyorli for ovarian cancer. Ownership rests with Five Arrows Principal Investments (Rothschild & Co), which invested in June 2021, and the company has executed a deliberate inorganic growth strategy with three acquisitions since 2020.
Sygnature Discovery firmographics
Firmographics- Name
- Sygnature Discovery
- Legal name
- Sygnature Discovery Limited
- Website
- https://sygnaturediscovery.com
- Company type
- Private
- Founded year
- 2003
- Operating status
- Operating
- Headcount range
- 1,001–5,000 employees
- Short description
- Sygnature Discovery is a UK-headquartered, privately held contract research organization delivering integrated preclinical drug discovery from target identification to clinical candidate nomination for global biotech and pharmaceutical clients, with 700+ scientists across the UK and Canada.
- Ownership category
- akta.pro rank
Sygnature Discovery industry classification
Industry- Product category
- Drug Discovery Contract Research
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714)
- SIC
- Services-Commercial Physical & Biological Research (8731)
- akta.pro primary industry
- Preclinical CROs (Discovery/Pharmacology/DMPK) (HLAGAAAB)
- akta.pro secondary industry
- Drug Discovery (Target ID/Validation & Hit Discovery) (HLAIALAA)
Keywords
Where Sygnature Discovery is headquartered
LocationHeadquarters
- HQ city
- Nottingham
- HQ country
- United Kingdom
- HQ region
- Europe
Offices6 records
Markets served
Sygnature Discovery business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Technology or R&D, Infrastructure, Operations, Marketing or Sales
Revenue model
- Integrated Drug Discovery Services: Full-service contract research organization providing end-to-end drug discovery programs from target identification through pre-clinical development. Revenue generated through project-based contracts, FTE allocation, milestone payments, and standalone service engagements.
- Standalone Scientific Services: Modular services including CADD, protein science, bioscience, chemistry, DMPK, in vivo pharmacology, and formulation offered as standalone engagements or integrated with full programs.
Go-to-market motion2 records
Distribution channels3 records
Marketing channels9 records
Sygnature Discovery product offering
Product offeringCore offering
Sygnature Discovery is a contract research organization providing integrated drug discovery services from target identification through to pre-clinical candidate nomination. The company delivers end-to-end programs as well as standalone scientific services spanning medicinal chemistry, computational chemistry and AI-driven drug design, bioscience, protein science and structural biology, DMPK, in vivo pharmacology, and formulation for biotech and pharmaceutical clients.
Product overview
Sygnature Discovery is a world-leading integrated drug discovery contract research organization (CRO) offering end-to-end preclinical drug discovery services from target identification to clinical candidate nomination. The core offering is Integrated Drug Discovery programs delivered through 700+ co-located multidisciplinary scientists across UK and North American sites. The service portfolio comprises Target Identification & Validation, HIT SYNERGY (Hit Identification), Hit-to-Lead, Lead Optimization, and Preclinical Development, supported by specialized Scientific Solutions including Computer Aided Drug Design (CADD) with AI capabilities, Bioinformatics, Virtual Screening, Structure-Based Drug Design, Protein Science & Structural Biology, Bioscience, Chemistry, DMPK, In Vivo Pharmacology, and Form & Formulation. Proprietary tools include SygDesign for informatics. The company integrates third-party AI platforms (DaltonTx, BullFrog AI, Iktos Makya) alongside its own capabilities. Modalities covered include small molecules, peptides, targeted protein degradation, ADCs, and biologics across therapeutic areas including oncology, immunology, neuroscience, and metabolic diseases. Since 2011, the company has delivered 61 pre-clinical compounds and 38 clinical compounds.
Differentiator
Problem solved
Functional benefit
Brands
- SygDesign: Proprietary informatics platform for compound design and data tracking
- HIT SYNERGY
- CHARMED
Products and services
- Integrated Drug Discovery Fully integrated drug discovery programs delivered by 700+ co-located multidisciplinary scientists from target identification through to candidate selection and pre-clinical development, with no internal drug pipeline.
- Target Identification & Validation AI-driven target identification and validation platform combining literature analysis, expert insights, and rigorous lab validation to guide targets through robust evaluation into hit discovery, for biotech and pharma clients.
- HIT SYNERGY (Hit Identification) Integrated hit identification service combining virtual screening, high-throughput screening, fragment screening, and affinity selection mass spectrometry to deliver high-quality, structurally diverse hits.
- Hit-to-Lead Hit assessment and optimization services including high-throughput chemistry, in silico profiling, core hopping, screening cascades, and in vitro ADME assays to deliver high-quality leads for biotech and pharma clients.
- Lead Optimization Multidisciplinary lead optimization combining medicinal chemistry, DMPK, safety assessment, and in vivo pharmacology to transform early leads into clinical-quality candidates with optimized potency, selectivity, and ADMET properties.
- Computer Aided Drug Design (CADD) AI-powered computational drug design service combining structure-based and ligand-based design, predictive modelling, virtual screening, ADMET prediction, bioinformatics, and secure collaborative data access.
- Bioinformatics End-to-end bioinformatics solutions supporting target identification, biomarker discovery, and translational decision-making through integrated analysis of transcriptomics, sequencing, and multi-omics data.
- Virtual Screening In silico virtual high-throughput screening using OpenEye Orion platform, enabling screening of billions of compounds in hours through structure-based and ligand-based techniques with curated and proprietary compound libraries.
- Structure-Based Drug Design Quantum-level structure-based drug design service integrating Fragment Molecular Orbital analysis, Molecular Dynamics simulations, and Relative Binding Free Energy calculations for precision compound optimization.
- Protein Science & Structural Biology High-quality protein production, purification, and characterization services including X-ray crystallography, cryo-EM, and macromolecular NMR for structural biology insights.
- Bioscience Tailored bioscience solutions including cell line generation, assay development, electrophysiology, high-throughput screening, and primary cells and tissues for target validation and lead optimization.
- Chemistry Global chemistry expertise spanning medicinal chemistry, synthetic chemistry, process and scale-up chemistry, NMR spectroscopy, separation sciences, high-throughput chemistry, and direct-to-biology approaches.
- Drug Metabolism and Pharmacokinetics (DMPK) Integrated DMPK solutions including in vitro ADME profiling, in vivo PK/PD studies, bioanalysis, biotransformation, and PK/PD modelling to support candidate nomination and IND applications.
- In Vivo Pharmacology High-quality in vivo pharmacology services across CNS/pain, metabolic disease, inflammation/immunology, and oncology models with pharmacokinetics, biomarkers, and exploratory toxicology capabilities.
- Form & Formulation Early clinical formulation, solid form analysis, salt and co-crystal screening, polymorph screening, and pre-clinical formulation services to support drug development and regulatory readiness.
- Modalities Drug Discovery (Small Molecules, Peptides, ADCs, Biologics, Targeted Protein Degradation) Modality-agnostic drug discovery spanning small molecules, peptides, targeted protein degradation (PROTACs, molecular glues), antibody-drug conjugates (ADCs), and biologics for biotech and pharma clients.
Quantifiable outcome
- 61 novel pre-clinical compounds delivered since 2011, with 38 progressed to clinical trials, 2 approved or under regulatory review
- +3 more outcomes
Companies that use Sygnature Discovery
Customer profileNamed customers7 records
Segments3 records
Ideal customer profiles3 records
Sygnature Discovery technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Integration3 records
AI capability8 records
Feature9 records
Sygnature Discovery partnerships and signals
Strategic signalPartnerships
Six partnerships are on record, tiered core.
- DaltonTxcoreStrategic collaboration with DaltonTx to incorporate their AI-powered Dalton drug discovery platform into Sygnature's computational and medicinal chemistry toolkit. Sygnature is conducting a retrospective evaluation of a legacy oncology programme involving a small-molecule clinical candidate in Phase I to assess platform benefits. The partnership includes SygDesign, BullFrog AI, and Iktos as existing integrated technologies.
- Iktoscore3-year collaboration for deployment of Iktos' AI technology Makya for generative AI in de novo molecular design and lead optimization. Iktos Makya is integrated into Sygnature's computational drug design workflows.
- BullFrog AIcoreIntegration of BullFrog AI's analysis platform into Sygnature's AI-enabled drug discovery capabilities, supporting target identification and validation workflows.
- OpenEyecoreLicensed use of OpenEye's Orion platform for ultra-high throughput virtual screening, molecular docking, and RBFE calculations using Non-Equilibrium Switching methodology.
- Pathios TherapeuticscoreStrategic partnership to discover novel GPR65 modulators for autoimmune disease treatment, applying integrated drug discovery capabilities.
- UBE CorporationcoreCollaboration with UBE Corporation to identify potent SHP2 degrader compounds using Sygnature's CHARMED PROTAC platform.
Scale indicators11 records
Recent moves9 records
Expansion highlights5 records
Sygnature Discovery competitors and assessment
Company assessmentBroad incumbents
- Eurofins Discovery: Eurofins Discovery is the drug discovery arm of Eurofins Scientific, offering medicinal chemistry, ADME/DMPK, and pharmacology services globally. While broader and more fragmented than Sygnature, it competes for similar biotech and pharma discovery outsourcing work and operates from European and US sites.
- WuXi AppTec: WuXi AppTec is one of the largest global CRO/CDMOs with a broad WuXi Discovery services platform (chemistry, biology, DMPK, in vivo) that competes with Sygnature for biotech and pharma discovery programmes. Geopolitical headwinds have begun redirecting Western sponsor programmes toward European-based CROs, putting Sygnature in a competitive position to gain share.
- Labcorp Drug Development: Labcorp Drug Development (formerly Covance) is a global CRO offering early discovery, pre-clinical, clinical and central lab services to pharma and biotech. Its Central Laboratory Services and Early Development divisions overlap directly with Sygnature's integrated drug discovery and DMPK offerings, making it a broad incumbent competitor.
- Charles River Laboratories: Charles River operates one of the largest global preclinical CRO footprints spanning discovery, safety assessment, and manufacturing services. Its Discovery & Safety Assessment segment directly overlaps Sygnature's integrated drug discovery and in vivo pharmacology offerings, and it competes head-to-head for large-pharma strategic partnership mandates.
Direct peers
- Curia (formerly AMRI): Curia is a global CDMO/CRO offering drug discovery, medicinal chemistry and pre-clinical development services alongside manufacturing. Its Discovery and Development segment competes with Sygnature for integrated discovery mandates from US-headquartered biotech and pharma sponsors.
- Domainex: Domainex is a UK-based integrated drug discovery CRO providing medicinal chemistry, biology, ADME and protein expression services to biotech and pharma sponsors. As a smaller UK-headquartered peer, it competes with Sygnature for early-stage biotech programmes and shares the same sovereign and regulatory operating environment.
- Concept Life Sciences: Concept Life Sciences is a UK-headquartered discovery CRO offering medicinal chemistry, in vitro ADME, structural biology and pharmacology services. It operates from a smaller scale than Sygnature but competes in similar enterprise biotech and pharma programmes, often as a specialist sub-segment participant.
- Pharmaron: Pharmaron is a China-headquartered, globally integrated CRO offering drug discovery, DMPK, pharmacology, and chemistry services with co-located multidisciplinary teams across US, UK and China sites. It competes with Sygnature for biotech and pharma discovery outsourcing mandates and operates at a similar integrated-services scale.
- Selvita: Selvita is a Kraków-based integrated drug discovery CRO providing medicinal chemistry, in vitro/in vivo pharmacology, DMPK and ADME services to biotech and pharma clients. It is one of the largest European-headquartered integrated discovery CROs and targets the same early-stage-to-clinical sponsor segment as Sygnature.
- Evotec SE: Evotec is a Hamburg-based integrated drug discovery CRO operating a comparable end-to-end platform (Target ID through pre-clinical) with similar co-located multidisciplinary teams. It is one of Sygnature's closest direct competitors in the small-molecule and biologics discovery space, sharing enterprise pharma and biotech sponsor lists and modality coverage.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights7 records
Customer concentration
Sygnature Discovery social profiles
Digital presenceSygnature Discovery financial estimates
Financial estimateRevenue estimate
Valuation estimate
Sygnature Discovery leadership team
Management profileNumber of profiles
Profiles6 records
Sygnature Discovery subsidiaries and ownership
Company hierarchySubsidiaries3 records
Sygnature Discovery funding detail
Funding detailFunding overview
Funding rounds2 records
Investors2 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Sygnature Discovery M&A and investment
M&A and investmentM&A3 records
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Sygnature Discovery
What does Sygnature Discovery do?
Sygnature Discovery is a contract research organization providing integrated drug discovery services from target identification through to pre-clinical candidate nomination. The company delivers end-to-end programs as well as standalone scientific services spanning medicinal chemistry, computational chemistry and AI-driven drug design, bioscience, protein science and structural biology, DMPK, in vivo pharmacology, and formulation for biotech and pharmaceutical clients.
Is Sygnature Discovery a public or private company?
Sygnature Discovery is a private company. It is classified as private equity controlled and is currently operating.
When was Sygnature Discovery founded?
Sygnature Discovery was founded in 2003. It employs 1,001 to 5,000 people.
Where is Sygnature Discovery based?
Sygnature Discovery is headquartered in Nottingham, United Kingdom, in the Europe region.
How does Sygnature Discovery make money?
Two revenue lines are on record. Integrated Drug Discovery Services are the primary driver. The others are standalone Scientific Services.
Who are Sygnature Discovery's main competitors?
Broad incumbents on record are Eurofins Discovery, WuXi AppTec, Labcorp Drug Development and Charles River Laboratories. Direct peers are Curia (formerly AMRI), Domainex, Concept Life Sciences, Pharmaron, Selvita and Evotec SE.
Does Sygnature Discovery have an API?
No public API is recorded for Sygnature Discovery.
What industry is Sygnature Discovery in?
Sygnature Discovery's product category is Drug Discovery Contract Research. Its primary akta.pro industry code is HLAGAAAB, Preclinical CROs (Discovery/Pharmacology/DMPK), with a secondary code of HLAIALAA, Drug Discovery (Target ID/Validation & Hit Discovery). Its NAICS code is 541714 and its SIC code is 8731.